Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZURITY Wins FDA Approval for DANZITEN™ Tablets with No Mealtime Restrictions
Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Product Name : Danziten
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna
Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Product Name : XS003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug
Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.
Product Name : Tasigna-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 23, 2023
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Aurobindo Pharma Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 12, 2021